NO20100041L - Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer - Google Patents
Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorerInfo
- Publication number
- NO20100041L NO20100041L NO20100041A NO20100041A NO20100041L NO 20100041 L NO20100041 L NO 20100041L NO 20100041 A NO20100041 A NO 20100041A NO 20100041 A NO20100041 A NO 20100041A NO 20100041 L NO20100041 L NO 20100041L
- Authority
- NO
- Norway
- Prior art keywords
- receptors
- increase
- treatment
- receptor
- diseases associated
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 229940075993 receptor modulator Drugs 0.000 title abstract 2
- 101710124361 Arylamine N-acetyltransferase 2 Proteins 0.000 title 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Det er beskrevet anvendelse av henholdsvis en ATreseptorantagonist eller av en ATreseptormodulator, eller et farmasøytisk akseptabelt salt derav, for fremstilling av et farmasøytisk preparat for behandling av lidelser eller sykdommer assosiert med økningen av ATreseptorer i subepitelområdet eller økning av ATreseptorer i epitelia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98811257 | 1998-12-23 | ||
EP98811258A EP1013273A1 (en) | 1998-12-23 | 1998-12-23 | Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors |
PCT/EP1999/010330 WO2000038676A1 (en) | 1998-12-23 | 1999-12-22 | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20100041L true NO20100041L (no) | 2001-08-16 |
Family
ID=26152118
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20013143A NO328775B1 (no) | 1998-12-23 | 2001-06-22 | Komprimerte tabletter omfattende valsartan. |
NO20100041A NO20100041L (no) | 1998-12-23 | 2010-01-12 | Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20013143A NO328775B1 (no) | 1998-12-23 | 2001-06-22 | Komprimerte tabletter omfattende valsartan. |
Country Status (26)
Country | Link |
---|---|
EP (3) | EP1140071B1 (no) |
JP (2) | JP2002533390A (no) |
KR (1) | KR100646716B1 (no) |
CN (2) | CN1304000C (no) |
AT (2) | ATE524176T1 (no) |
AU (4) | AU3043000A (no) |
BR (1) | BR9916576A (no) |
CA (2) | CA2622805C (no) |
CY (2) | CY1106581T1 (no) |
CZ (2) | CZ297795B6 (no) |
DE (1) | DE69935249T2 (no) |
DK (2) | DK1588706T3 (no) |
ES (2) | ES2373556T3 (no) |
HK (1) | HK1038888B (no) |
HU (1) | HUP0104780A3 (no) |
ID (1) | ID29856A (no) |
IL (5) | IL143233A0 (no) |
NO (2) | NO328775B1 (no) |
NZ (3) | NZ587909A (no) |
PL (1) | PL199100B1 (no) |
PT (2) | PT1588706E (no) |
RU (3) | RU2271809C2 (no) |
SI (2) | SI1588706T1 (no) |
SK (1) | SK9132001A3 (no) |
TR (7) | TR200805740T1 (no) |
WO (1) | WO2000038676A1 (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001097805A2 (en) * | 2000-06-22 | 2001-12-27 | Novartis Ag | Solid valsartan pharmaceutical compositions |
JP4972847B2 (ja) * | 2000-10-11 | 2012-07-11 | 住友化学株式会社 | コラーゲン蓄積抑制剤 |
JPWO2002083127A1 (ja) * | 2001-04-09 | 2004-09-30 | 宮田 敏男 | 蛋白修飾物生成抑制組成物 |
DE60222409T2 (de) | 2001-05-31 | 2008-09-25 | Vicore Pharma Ab | Trizyklische verbindungen, nützlich als angiotensin ii agonisten |
CA2466659A1 (en) * | 2001-11-13 | 2003-05-22 | Takeda Chemical Industries, Ltd. | Anticancer agents |
EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
EP1680095A2 (en) * | 2003-11-03 | 2006-07-19 | Zentiva, a.s. | Valsartan containing formulation |
PT1830869E (pt) * | 2004-12-24 | 2013-08-22 | Spinifex Pharm Pty Ltd | Método de tratamento ou profilaxia |
EA015108B1 (ru) | 2004-12-24 | 2011-06-30 | КРКА, д.д., НОВО МЕСТО | Способ получения твердой фармацевтической композиции, содержащей валсартан |
WO2006136916A2 (en) * | 2005-06-20 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same |
GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
ES2246742B1 (es) * | 2005-09-06 | 2007-02-01 | Prous Institute For Biomedical Research S.A. | Uso de un derivado de imidazol. |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
EP2139473A1 (en) * | 2007-03-29 | 2010-01-06 | Alembic Limited | Valsartan tablet formulations |
TR200703568A1 (tr) | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formülasyonları |
KR20100091963A (ko) | 2007-10-09 | 2010-08-19 | 노파르티스 아게 | 발사르탄의 제약적 제형 |
ES2536514T3 (es) * | 2007-11-06 | 2015-05-26 | Novartis Ag | Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP) |
US20110104166A1 (en) * | 2008-01-18 | 2011-05-05 | Stankovic Konstantina M | Methods and Compositions for Treating Polyps |
GB0802931D0 (en) * | 2008-02-18 | 2008-03-26 | Queen Mary & Westfield College | Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions |
EP2405899A2 (en) | 2009-03-11 | 2012-01-18 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Valsartan formulations |
WO2011102702A2 (en) | 2010-02-16 | 2011-08-25 | Krka, D. D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
EP2455388A1 (en) | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
CN102266307B (zh) * | 2011-08-01 | 2012-10-24 | 海南锦瑞制药股份有限公司 | 一种缬沙坦胶囊及其制备方法 |
WO2013098578A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
WO2013098576A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
EA018867B1 (ru) * | 2012-11-01 | 2013-11-29 | Лаборатория Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции и продукт способа |
JP2022542437A (ja) | 2019-08-02 | 2022-10-03 | ランティオペプ ベスローテン ヴェンノーツハップ | 癌の処置に用いるアンジオテンシン2型(at2)受容体アゴニスト |
EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
WO2024026528A1 (en) * | 2022-08-02 | 2024-02-08 | Dimerix Bioscience Pty Ltd | Dosage regimen for the treatment of copd |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3146168A (en) * | 1962-04-10 | 1964-08-25 | Fmc Corp | Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
DE68916983T2 (de) * | 1988-02-25 | 1995-01-19 | Yamanouchi Europ Bv | Verfahren zur Herstellung eines pharmazeutischen Granulats. |
EP0955294B1 (en) | 1989-06-14 | 2003-09-24 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acid |
IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
DK0443983T3 (da) * | 1990-02-19 | 1996-03-18 | Ciba Geigy Ag | Acrylforbindelser |
TW201738B (no) | 1990-03-20 | 1993-03-11 | Sanofi Co | |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
IL99246A0 (en) | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
WO1992005784A1 (en) * | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
DE4038335A1 (de) * | 1990-12-01 | 1992-06-04 | Boehringer Mannheim Gmbh | Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel |
SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5591762A (en) * | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
DE4132632A1 (de) * | 1991-10-01 | 1993-04-08 | Bayer Ag | Substituierte imidazolyl-propensaeurederivate |
DE4309968A1 (de) * | 1993-03-26 | 1994-09-29 | Bayer Ag | Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten |
JPH07505646A (ja) | 1992-04-13 | 1995-06-22 | ゼネカ・リミテッド | 神経伝達速度の減損を伴う障害,特に糖尿病性ニューロパシーに対するアンギオテンシンiiアンタゴニスト |
US5610153A (en) | 1992-12-11 | 1997-03-11 | Ciba-Geigy Corporation | Benzazepinone derivatives |
US5683997A (en) * | 1992-12-11 | 1997-11-04 | Ciba-Geigy Corporation | Substituted benzazepinones |
DE4309963A1 (de) * | 1993-03-26 | 1994-09-29 | Hubert Kamperschroer | Faß zum Austragen von Gülle |
FR2716882B1 (fr) * | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
DE4408497A1 (de) * | 1994-03-14 | 1995-09-21 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
SK117996A3 (en) * | 1994-03-17 | 1997-03-05 | Ciba Geigy Ag | Pharmaceutical composition for treatment of diabetic nephropathy |
DE4432860A1 (de) * | 1994-09-15 | 1996-03-21 | Merck Patent Gmbh | Imidazopyridine |
ATE225657T1 (de) | 1995-10-06 | 2002-10-15 | Novartis Erfind Verwalt Gmbh | Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren |
WO1997031624A1 (en) | 1996-02-27 | 1997-09-04 | Purdue Research Foundation | Liposomal delivery system |
DE69718146T2 (de) * | 1996-02-29 | 2003-10-02 | Novartis Ag | At1 rezeptor antagonist zur anregung von apoptosis |
GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
DE19628617A1 (de) * | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
SG142116A1 (en) | 1998-07-10 | 2008-05-28 | Novartis Ag | Antihypersensitive combination of valsartan and calcium channel blocker |
BR0007686A (pt) * | 1999-01-26 | 2001-11-06 | Novartis Ag | Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda |
WO2001097805A2 (en) * | 2000-06-22 | 2001-12-27 | Novartis Ag | Solid valsartan pharmaceutical compositions |
US20070123498A1 (en) | 2003-10-17 | 2007-05-31 | Shetty Suraj S | Combination of organic compounds |
JP2009018990A (ja) | 2005-10-25 | 2009-01-29 | Univ Kurume | C型肝炎ウイルス由来ペプチド |
-
1999
- 1999-12-22 CZ CZ20032559A patent/CZ297795B6/cs not_active IP Right Cessation
- 1999-12-22 ES ES05013209T patent/ES2373556T3/es not_active Expired - Lifetime
- 1999-12-22 EP EP99964665A patent/EP1140071B1/en not_active Revoked
- 1999-12-22 SI SI9931064T patent/SI1588706T1/sl unknown
- 1999-12-22 AT AT05013209T patent/ATE524176T1/de active
- 1999-12-22 TR TR2008/05740T patent/TR200805740T1/xx unknown
- 1999-12-22 PT PT05013209T patent/PT1588706E/pt unknown
- 1999-12-22 CA CA2622805A patent/CA2622805C/en not_active Expired - Fee Related
- 1999-12-22 TR TR2006/05471T patent/TR200605471T2/xx unknown
- 1999-12-22 CZ CZ20012306A patent/CZ293257B6/cs not_active IP Right Cessation
- 1999-12-22 EP EP10010334A patent/EP2298298A3/en not_active Withdrawn
- 1999-12-22 TR TR2002/00764T patent/TR200200764T2/xx unknown
- 1999-12-22 CN CNB998150452A patent/CN1304000C/zh not_active Expired - Fee Related
- 1999-12-22 SI SI9930963T patent/SI1140071T1/sl unknown
- 1999-12-22 AU AU30430/00A patent/AU3043000A/en not_active Abandoned
- 1999-12-22 TR TR2001/01784T patent/TR200101784T2/xx unknown
- 1999-12-22 DK DK05013209.1T patent/DK1588706T3/da active
- 1999-12-22 TR TR2008/05741T patent/TR200805741T2/xx unknown
- 1999-12-22 JP JP2000590630A patent/JP2002533390A/ja not_active Withdrawn
- 1999-12-22 CA CA002351357A patent/CA2351357A1/en not_active Abandoned
- 1999-12-22 PT PT99964665T patent/PT1140071E/pt unknown
- 1999-12-22 NZ NZ587909A patent/NZ587909A/en not_active IP Right Cessation
- 1999-12-22 DE DE69935249T patent/DE69935249T2/de not_active Revoked
- 1999-12-22 AT AT99964665T patent/ATE354364T1/de not_active IP Right Cessation
- 1999-12-22 WO PCT/EP1999/010330 patent/WO2000038676A1/en active IP Right Grant
- 1999-12-22 BR BR9916576-7A patent/BR9916576A/pt not_active IP Right Cessation
- 1999-12-22 IL IL14323399A patent/IL143233A0/xx not_active IP Right Cessation
- 1999-12-22 KR KR1020017007996A patent/KR100646716B1/ko not_active IP Right Cessation
- 1999-12-22 HU HU0104780A patent/HUP0104780A3/hu unknown
- 1999-12-22 NZ NZ511938A patent/NZ511938A/xx not_active IP Right Cessation
- 1999-12-22 CN CNA200410087973XA patent/CN1636561A/zh active Pending
- 1999-12-22 ID IDW00200101299Q patent/ID29856A/id unknown
- 1999-12-22 TR TR2006/05472T patent/TR200605472T1/xx unknown
- 1999-12-22 DK DK99964665T patent/DK1140071T3/da active
- 1999-12-22 SK SK913-2001A patent/SK9132001A3/sk unknown
- 1999-12-22 ES ES99964665T patent/ES2281978T3/es not_active Expired - Lifetime
- 1999-12-22 RU RU2001119990/15A patent/RU2271809C2/ru not_active IP Right Cessation
- 1999-12-22 EP EP05013209A patent/EP1588706B1/en not_active Revoked
- 1999-12-22 PL PL349424A patent/PL199100B1/pl not_active IP Right Cessation
- 1999-12-22 NZ NZ553010A patent/NZ553010A/en not_active IP Right Cessation
- 1999-12-22 TR TR2008/05275T patent/TR200805275T2/xx unknown
-
2001
- 2001-05-17 IL IL143233A patent/IL143233A/en not_active IP Right Cessation
- 2001-06-22 NO NO20013143A patent/NO328775B1/no not_active IP Right Cessation
-
2002
- 2002-01-28 HK HK02100661.6A patent/HK1038888B/zh not_active IP Right Cessation
-
2003
- 2003-12-02 AU AU2003266433A patent/AU2003266433B2/en not_active Ceased
-
2005
- 2005-08-01 RU RU2005124363/15A patent/RU2361575C2/ru not_active IP Right Cessation
-
2006
- 2006-07-18 AU AU2006203077A patent/AU2006203077B2/en not_active Expired
- 2006-11-02 IL IL179015A patent/IL179015A0/en unknown
- 2006-11-02 IL IL179017A patent/IL179017A0/en unknown
- 2006-11-02 IL IL179016A patent/IL179016A0/en unknown
-
2007
- 2007-05-10 CY CY20071100642T patent/CY1106581T1/el unknown
-
2008
- 2008-11-05 RU RU2008143545/15A patent/RU2008143545A/ru unknown
-
2009
- 2009-09-24 AU AU2009220022A patent/AU2009220022B2/en not_active Expired
-
2010
- 2010-01-12 NO NO20100041A patent/NO20100041L/no not_active Application Discontinuation
- 2010-01-18 JP JP2010008140A patent/JP5254258B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-06 CY CY20111101213T patent/CY1112395T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20100041L (no) | Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer | |
BRPI0411699A (pt) | compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos | |
ES2091877T3 (es) | Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia. | |
CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
EA200200106A1 (ru) | Фармацевтическая композиция леводопа/карбидопа/энтакапон | |
WO1997020823A3 (en) | 2-amino quinazoline derivatives as npy receptor antagonists | |
SG188700A1 (en) | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors | |
DK1608349T3 (da) | Oralt tilförselssystem omfattende et antibakterielt og et antiinflammatorisk middel | |
EA200100089A1 (ru) | Предотвращение рецидива мигрени | |
BRPI0316895B8 (pt) | composto, processo para a preparação do composto, composição farmacêutica e uso do composto | |
AR023687A1 (es) | Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa | |
EE200100520A (et) | N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena | |
ATE266029T1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
TNSN99158A1 (ar) | طريقة لمنع الاصابة بالربو | |
AR018825A1 (es) | Antagonistas del receptor de bradiquinina no peptidica para uso en el tratamiento de trastornos y enfermedades oftalmicas | |
PT942729E (pt) | Utilizacao de antagonistas de receptores nk-1 para tratamento de doencas do stresse | |
SE9304236D0 (sv) | New use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |